AstraZeneca to discontinue Epanova trial following disappointing data

AstraZeneca PLC said Monday that it will discontinue the trial for the drug Epanova following a recommendation from an independent data-monitoring committee.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.